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Abstract Text: 
 
Study question 
 
Does culturing pre-implantation embryos in the presence of a TGF (transforming growth factor) 
β pathway inhibitor support the mouse embryonic stem cells (mESCs) derivation and does the 
extra inhibition of TGFβ signaling during culture of mESCs derived in '2i' conditions impose an 
altered state of pluripotency in stem cells? 
 
 
Summary answer 
 
Culturing mouse embryos in the presence of the TGFβ pathway inhibitor, SB431542 (SB) 
permits the derivation of mESCs with efficiency up to 100%. mESCs derived in 2i conditions 
show significantly higher expression of naive and other pluripotency markers when additionally 
exposed to SB during culture. 
 
 
What is known already? 
 
ESCs exist in a naive or primed state of pluripotency regulated by distinct signaling pathways, 
mostly antagonizing each other. Although naive ESCs are more homogeneous in terms of 
pluripotency, culture conditions can influence this phenomenon. For example, mESCs derived in 
2i conditions (dual inhibition of fibroblast-growth-factor and glycogen-synthase-kinase pathways 
with PD0325901 and CHIR99021 respectively) are designated to be in the ground-state of 
pluripotency with better homogeneity than those derived in leukemia-inhibitory-factor and serum 
conditions. 
  
Study design, size, duration 
Embryos were cultured with/without SB supplementation from the morula stage onwards. 
Blastocysts were plated in the following mESCs derivation-conditions: 1)2i, 2)3i(2i+SB), 3)SB 
and 4) control without small molecule inhibitors.mESCs derived in 2i were further cultured in 2i 
vs 3i for six passages. Naive-pluripotency characteristics were evaluated by RT-qPCR. 
 
 
Participants/materials, setting, methods 
 
5 control embryos and 77 embryos cultured in SB from the morula stage were plated in the 
aforementioned conditions. Levels of expression of Oct4, Sox2, Nanog, Rex1, Pecam1, Stella, 
Fgf5 and Gbx2 were examined by RT-qPCR in three 2i-derived mESCs lines and in subsequent 
mESCs cultures further maintained in 3i. 
 
 
Main results and the role of chance 
 
The derivation efficiency of mESCs from control embryos was 63.3%, 83.3%, 0%, 0% and that 
from embryos cultured in SB was 91.3%, 100%, 0%, 0% in the four aforementioned conditions 
respectively. When 2i lines were subsequently cultured in 3i, naïve and pluripotency genes were 
expressed more than 2-fold higher in 3i compared to those maintained in 2i. Naïve markers such 
as Pecam-1 and Stella and the pluripotency marker Nanog increased significantly (p<0.05) in all 
cases in 3i. Oct4, Sox2 and Rex1 were also significantly up-regulated while the mesodermal 
marker FGF5 was significantly down-regulated in 2 out of 3 cell lines cultured in 3i. No 
significant difference between the two conditions was seen in the level of Gbx2, a post-
implantation primitive ectodermal marker. 
 
Limitations, reason for caution 
Our results show that inhibition of TGFβ signaling in existing mESCs can modulate the 
pluripotency state of cells. Additional experiments such as functional differentiation tests, 
heterogeneity and larger-scale transcriptome-analysis of the cell lines maintained in 2i and 3i 
must be performed to better understand the differences between these pluripotent states. 
 
Wider implications of the findings 
Naive mESCs exhibit heterogeneity to a lesser extent than primed ones. So, devising a condition 
in which the cell population shows least heterogeneity merits further investigation and would be 
beneficial for future clinical use of ESCs. Our work will also serve to maintain a more robust 
pluripotent state in mESCs. 
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